Ltd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

by · The Markets Daily

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) major shareholder Ltd. Kck sold 223,991 shares of NeuroPace stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $5.45, for a total value of $1,220,750.95. Following the completion of the transaction, the insider now directly owns 5,270,845 shares of the company’s stock, valued at $28,726,105.25. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

  • On Wednesday, October 23rd, Ltd. Kck sold 147 shares of NeuroPace stock. The stock was sold at an average price of $6.02, for a total transaction of $884.94.
  • On Monday, October 21st, Ltd. Kck sold 3,720 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total transaction of $22,692.00.
  • On Friday, October 18th, Ltd. Kck sold 4,878 shares of NeuroPace stock. The shares were sold at an average price of $6.29, for a total transaction of $30,682.62.
  • On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
  • On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total value of $26,362.74.
  • On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total value of $16,332.20.
  • On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total value of $19,050.30.
  • On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total transaction of $32,700.60.
  • On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total transaction of $23,126.46.

NeuroPace Stock Performance

NPCE stock opened at $6.93 on Thursday. NeuroPace, Inc. has a 1-year low of $5.45 and a 1-year high of $18.15. The business’s 50-day moving average price is $6.93 and its two-hundred day moving average price is $7.94. The firm has a market cap of $202.34 million, a PE ratio of -6.36 and a beta of 1.78. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97.

NeuroPace (NASDAQ:NPCE – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business had revenue of $19.26 million during the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 195.26% and a negative net margin of 41.63%. NeuroPace’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.36) EPS. As a group, research analysts forecast that NeuroPace, Inc. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on NPCE. Wells Fargo & Company dropped their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a research note on Wednesday, August 14th. Finally, Morgan Stanley decreased their target price on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.00.

Get Our Latest Research Report on NeuroPace

Institutional Investors Weigh In On NeuroPace

Large investors have recently made changes to their positions in the stock. Rhumbline Advisers bought a new stake in NeuroPace in the 2nd quarter valued at $111,000. Financial Advocates Investment Management raised its stake in shares of NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after purchasing an additional 5,000 shares during the period. Hillsdale Investment Management Inc. acquired a new position in shares of NeuroPace during the first quarter worth about $155,000. XTX Topco Ltd grew its holdings in shares of NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after buying an additional 8,643 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in NeuroPace in the 2nd quarter valued at approximately $257,000. Institutional investors own 78.83% of the company’s stock.

About NeuroPace

(Get Free Report)

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Further Reading